



(51) International Patent Classification:

C07D 241/18 (2006.01) C07D 498/10 (2006.01)
C07D 241/20 (2006.01) C07D 471/10 (2006.01)
C07D 401/14 (2006.01) A61K 31/497 (2006.01)
C07D 401/04 (2006.01) A61P 35/00 (2006.01)
C07D 491/107 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/IB2018/051973

(22) International Filing Date:

23 March 2018 (23.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2017/051690

23 March 2017 (23.03.2017) IB

(71) Applicants: **JACOBIO PHARMACEUTICALS CO., LTD.** [CN/CN]; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **JACOBIO-ALPHA PHARMACEUTICALS CO., LTD.** [CN/CN]; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN).

(72) Inventors: **MA, Cunbo**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **GAO, Panliang**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **HU, Shaojing**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **XU, Zilong**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **HAN, Huifeng**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **WU, Xinping**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development

Area, Daxing, Beijing 101111 (CN). **KANG, Di**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). **LONG, Wei**; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS



Formula I

(57) Abstract: This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

